Category: Health

The coroner’s findings suggest that the death of Lady Joan Branson could have been avoided with timely administration of blood thinners following her fall on Necker Island.

A British coroner has concluded that the death of Lady Joan Branson, the wife of billionaire Richard Branson, could have been prevented with the timely use of blood-thinning medication. Lady Branson passed away at the age of 80 after being admitted to a hospital in November 2025, following a fall weeks earlier on Necker Island, a private island owned by her husband.

The cause of her death was identified as a pulmonary embolism, which occurs when a blood clot travels to the lungs and blocks an artery, as reported by the BBC. This condition was attributed to deep vein thrombosis (DVT), a serious complication that can arise after prolonged immobility.

During a recent inquest at Westminster Coroner’s Court, Senior Coroner Fiona Wilcox stated that Lady Branson did not receive preventive anticoagulants, commonly known as blood thinners, despite being at a “very high risk of developing deep vein thrombosis.” The coroner highlighted that Lady Branson’s immobility following her fracture was a significant risk factor contributing to her condition.

Wilcox remarked, “I do find her death would have likely been prevented, and the lack of anticoagulation did cause or contribute to her death probably.” However, she clarified that the case was not one of neglect, as Lady Branson did receive medical care during her hospital stay. The purpose of the inquest was to “explore the facts, come to the correct conclusions, and learn lessons from this,” according to The Independent.

Throughout the inquest, medical professionals provided conflicting testimonies regarding whether the risk of bleeding justified withholding the anticoagulant medication, specifically enoxaparin, which is commonly used to prevent blood clots in hospitalized patients.

Dr. Basir Kunduzi, the admitting physician, testified that he did not conduct a bleeding risk assessment on the day of Lady Branson’s admission. He expressed that her death prompted him to reflect on his responsibilities as a physician and the importance of effective communication among medical team members.

The findings from the inquest underscore the critical role that blood thinners can play in preventing DVT, especially in patients who are unable to move normally due to surgery, fractures, or extended bed rest. While these medications can increase the risk of bleeding, medical professionals generally weigh the potential benefits against the risks before administering them.

Dr. Jared Ross, an emergency medicine physician based in South Carolina, emphasized the importance of blood clot prevention in hospitalized adults. He stated, “In the vast majority of cases, the benefits outweigh the risks.” Dr. Ross was not involved in Lady Branson’s care or the inquest.

A spokesperson for Sir Richard Branson indicated that the family does not plan to comment further on the inquest, but referenced the numerous heartfelt social media posts made by Sir Richard in memory of his wife. In an emotional tribute on Instagram last year, he described Lady Branson as the “shining star” of their family, stating, “Life will never be the same without her. But we have fifty incredible years of memories — years filled with tears and laughter, kindness, and a love that shaped our family more than words could ever capture.” He added, “It was a relationship that worked. We just had lots of laughs. We were very lucky.”

While pulmonary embolisms can be life-threatening, prompt treatment significantly enhances the chances of survival, making early recognition of symptoms critical. According to the Centers for Disease Control and Prevention (CDC), symptoms of DVT may include swelling, pain or tenderness, warmth, and redness in the affected leg or arm. A pulmonary embolism may present with symptoms such as shortness of breath, chest pain that worsens with deep breathing or coughing, a rapid or irregular heartbeat, coughing up blood, lightheadedness, or fainting.

The CDC and the National Heart, Lung, and Blood Institute advise that anyone experiencing symptoms of a pulmonary embolism should seek immediate medical attention.

These findings highlight the importance of timely medical intervention and the potential consequences of overlooking preventive measures in healthcare settings, particularly for patients at high risk for complications such as DVT and pulmonary embolism, according to BBC.

Recent research from Hong Kong suggests that nitrogen-containing bisphosphonates, commonly used for osteoporosis, may lower the risk of Alzheimer’s disease by 16% among older adults.

A large-scale study conducted in Hong Kong has found a significant link between the use of nitrogen-containing bisphosphonates (NBPs) for osteoporosis and a reduced risk of Alzheimer’s disease and other forms of dementia. The research involved 121,492 adults aged 60 and older, revealing that those who used these medications had a 16% lower risk of developing Alzheimer’s compared to those who did not take osteoporosis drugs. Furthermore, the risk was found to be 24% lower when compared to individuals using other types of osteoporosis medications.

Nitrogen-containing bisphosphonates are a class of drugs designed to slow bone loss and decrease the risk of fractures, particularly in individuals diagnosed with osteoporosis. Common examples of these medications include alendronate, ibandronate, risedronate, and zoledronate. Osteoporosis is a condition characterized by weakened bones, making them more susceptible to fractures, and is particularly prevalent among older adults, as noted by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

All participants in the Hong Kong study had either recently been diagnosed with osteoporosis or had experienced a serious fracture in the spine, humerus, wrist, or hip. Importantly, none of the participants had previously received treatment for osteoporosis.

Ching-Lung Cheung, an associate professor in the Department of Pharmacology and Pharmacy at the University of Hong Kong’s Li Ka Shing Faculty of Medicine, emphasized the emerging evidence of a connection between bone health and brain health. “Emerging evidence points to a bone-brain axis, suggesting a close link between bone and brain health,” Cheung stated. “Our previous studies and those of others have found that people with low bone mass or osteoporosis are more likely to develop dementia later in life. This highlights the importance of maintaining good bone health, which may also help reduce the risk of dementia.”

The findings of this observational study were published in the journal Alzheimer’s & Dementia. However, Cheung cautioned that the results do not establish a definitive cause-and-effect relationship between bisphosphonate use and reduced dementia risk. “Our findings therefore do not prove that bisphosphonate use reduces dementia risk; this needs confirmation in a clinical trial,” he noted.

Another important consideration raised by the researchers is the generalizability of the study’s findings, as the research was conducted solely within a Chinese population. This raises questions about whether the results can be applied to other demographic groups. Additionally, the study lacked baseline cognitive testing, which means that participants who may have already had cognitive impairments might have been less likely to receive osteoporosis treatment.

The researchers also acknowledged limitations regarding the severity of osteoporosis and bone fractures among participants, as well as the absence of data on their use of over-the-counter calcium and vitamin D supplements. External factors such as education level, social isolation, air pollution, and vision loss could also influence dementia risk, further complicating the findings.

While the study indicates that older patients receiving NBPs for osteoporosis or fragility fractures had lower rates of Alzheimer’s and related dementias, the authors caution against prescribing bisphosphonates specifically for dementia prevention or treatment at this stage.

Cheung and his team called for further research to include a more diverse population and to explore whether gender might play a role in the observed reduced risk. “The next step is to confirm our observational findings in a clinical trial,” Cheung stated. “If the benefit is demonstrated, it could have important implications for dementia management.” The researchers hope that their findings will encourage both patients and healthcare professionals to consider the overall benefits and risks associated with osteoporosis treatment.

According to Fox News Digital, the implications of this study could pave the way for new approaches in managing dementia risk among older adults.

A recent study has linked the antibiotic cefepime to a significantly higher risk of all-cause mortality in adults compared to other beta-lactam antibiotics, raising concerns about its safety.

A new study has raised alarms regarding the antibiotic cefepime, commonly used to treat various bacterial infections. The research indicates that cefepime may be associated with a 94.4% higher probability of all-cause mortality compared to other beta-lactam drugs.

Cefepime is typically administered via injection in clinical settings to treat conditions such as pneumonia, urinary tract infections (UTIs), and skin infections. While it is effective against a wide range of bacteria, severe side effects can occur, particularly in older patients and those with kidney issues. According to the Mayo Clinic, these side effects may include confusion, decreased consciousness, and seizures.

The global study, published in JAMA Network Open, analyzed data from 110 randomized clinical trials involving over 22,000 patients who received cefepime or another beta-lactam antibiotic. The patient population included both adults and children treated for febrile neutropenia, a serious medical condition characterized by fever and critically low levels of infection-fighting white blood cells, as well as pneumonia, severe bacterial infections, UTIs, and meningitis.

Across all trials, 778 deaths were recorded among 11,726 patients (6.6%) who received cefepime, compared to 6.2% of those treated with alternative antibiotics. Researchers focused on deaths from any cause occurring approximately 30 days after treatment.

Using a Bayesian meta-analysis, the researchers determined a 94.4% probability that cefepime was linked to higher all-cause mortality compared to other beta-lactam antibiotics. When the analysis was narrowed to 73 peer-reviewed published trials, this probability increased to 98.6%. The association appeared to be stronger in adults than in children, particularly among patients treated for febrile neutropenia.

Despite these findings, cefepime remains a widely used broad-spectrum antibiotic for serious bacterial infections in hospitalized patients due to its effectiveness against a variety of bacteria. The researchers did not recommend discontinuing its use but emphasized the need for further research and guidance to better understand its safety profile.

Several factors may explain the observed association between cefepime and increased mortality, although the researchers did not pinpoint a single cause. Potential explanations include inadequate drug levels that fail to effectively treat infections and neurotoxicity, which can occur when drug levels are excessively high.

Finding the appropriate dosage of cefepime can be challenging. Higher doses may enhance its ability to combat bacteria but also raise the risk of toxic side effects. The study did have limitations, including the combination of clinical trials with varying designs, patient populations, dosing strategies, and comparison antibiotics, some of which date back several decades. Importantly, the analysis identified an association rather than proving that cefepime itself caused higher mortality rates.

Dr. Marc Siegel, a senior medical analyst at Fox News, highlighted the significance of re-evaluating older studies in light of these findings. He noted that febrile neutropenia itself is a major cause of death in this patient population, complicating the determination of whether cefepime treatment decreases or potentially increases this risk. Dr. Siegel, who was not involved in the research, suggested that both underdosing and overdosing may be more closely linked to poorer outcomes and higher mortality rates, indicating that appropriate dosing could be crucial.

He also proposed that artificial intelligence could play a role in determining the optimal dosage of cefepime and assessing patient outcomes more effectively.

As the medical community continues to evaluate the safety of cefepime, these findings underscore the importance of careful monitoring and dosage adjustments for patients receiving this antibiotic.

For more information, refer to the study published in JAMA Network Open.

A recent study has linked popular GLP-1 weight-loss drugs to a rare brain disorder, raising concerns about vitamin B1 deficiency among users.

Researchers are sounding the alarm over a rare but potentially life-threatening brain condition associated with popular GLP-1 weight-loss medications. A new study published in Clinical Nutrition has identified 15 reported cases of Wernicke encephalopathy, a neurological disorder stemming from severe vitamin B1 deficiency, in individuals taking GLP-1 receptor agonists.

The majority of these reported cases involved semaglutide, marketed under the brand names Ozempic and Wegovy, as well as tirzepatide, sold as Mounjaro and Zepbound. The researchers uncovered these cases through the FDA’s Adverse Event Reporting System (FAERS), published medical literature, and their own medical center.

Patients in the study commonly reported gastrointestinal symptoms or nutritional issues, including weight loss, vomiting, loss of appetite, or malnutrition. Notably, the incidence of Wernicke encephalopathy appeared more frequently among those using GLP-1 medications compared to individuals taking other drugs. However, the researchers stressed that the study does not establish a direct causal link between the medications and the condition.

Vitamin B1 plays a crucial role in brain function, and severe deficiencies can lead to confusion, difficulty walking, balance issues, and changes in vision. If left untreated, Wernicke encephalopathy can result in permanent neurological damage or even death.

Karthik Achari, a clinician based in Chicago and founder of PepMD, emphasized the need to view the findings in context. “Researchers went through adverse event reports and the medical literature and found a small number of cases—15—of Wernicke encephalopathy in people taking GLP-1 drugs,” Achari told Fox News Digital. “That’s out of millions of people on these medications. So this is rare.”

However, he acknowledged the seriousness of the findings. “It’s real, it’s serious, and the mechanism makes sense,” he added. Achari explained that GLP-1 medications can suppress appetite while also causing nausea and vomiting, which may lead some individuals to become deficient in vitamin B1.

“The drug shrinks your appetite. It doesn’t shrink your body’s requirements,” he noted. “You can now eat very little without feeling it, which is the point of the medication, but your need for protein, vitamins, and fluids didn’t go anywhere.” Individuals experiencing persistent nausea and vomiting, rapid weight loss while consuming minimal food, those with a history of bariatric surgery, and heavy alcohol users may be at a heightened risk for vitamin B1 deficiency.

Erin Palinski-Wade, a New Jersey-based nutritionist and author of The Sleepdemic Solution, stressed the importance of proper nutrition and hydration as part of the treatment plan for those taking GLP-1 medications. “GLP-1 medications can dramatically reduce appetite, but that also means people may unintentionally under-eat the very things their bodies need most, especially protein, fiber, and fluids,” she told Fox News Digital.

Palinski-Wade also warned that ongoing vomiting or diarrhea can increase the risk of dehydration and kidney problems. She advised patients to seek medical guidance if these symptoms persist for approximately 24 hours. “Don’t assume every side effect is just part of being on a GLP-1,” she cautioned. “Severe or persistent symptoms deserve attention.”

The researchers acknowledged that their study relied heavily on reports submitted to the FDA and cannot definitively prove that GLP-1 medications caused Wernicke encephalopathy. They called for further research to explore this potential link. Experts have advised that patients should not discontinue their prescribed GLP-1 medications based solely on these findings.

Fox News Digital reached out to Novo Nordisk, Eli Lilly, and the researchers for comment regarding the study and its implications.

Regular consumption of very hot coffee and tea is associated with a significantly increased risk of esophageal cancer, according to a new study from the University of Oxford involving nearly 1 million adults.

A recent study conducted by researchers at the University of Oxford has revealed a concerning link between the consumption of very hot beverages and an increased risk of esophageal squamous cell carcinoma (SCC). The study, which involved nearly 1 million adults, found that individuals who reported drinking tea or coffee at very high temperatures had approximately three times the risk of developing this type of cancer compared to those who preferred their drinks warm.

The research indicated that drinking six or more hot beverages daily was associated with a 71% higher risk of SCC. However, the same correlation was not observed for esophageal adenocarcinoma (AC), a different type of cancer that arises in the lower part of the esophagus.

Lead study author Keren Papier, a nutritional epidemiologist at the University of Oxford, emphasized the significance of the findings. The study is noted as the largest of its kind to date, with participants drawn from two major studies: the Million Women Study (MWS) and the UK Biobank (UKB). Participants in the MWS were followed for an average of 14 years, while those in the UKB were monitored for 11 years.

“Compared with people who reported drinking their beverages ‘warm,’ those who drank them ‘hot’ had around a 1.7 times higher risk of SCC, while those who drank them ‘very hot’ had around a three times higher risk,” Papier explained in an interview.

The findings were published in the International Journal of Cancer, highlighting the potential public health implications of beverage temperature on cancer risk. The researchers estimated that if the observed association reflects a true cause-and-effect relationship, approximately 14% of SCC cases could potentially be prevented if individuals opted for beverages at a “hot” temperature rather than “very hot.”

However, the study does have limitations. The researchers noted that beverage temperatures were self-reported rather than directly measured, which could lead to variability in how participants classified the temperatures of their drinks. “A limitation of our study was that, although we examined associations by self-reported preferred drink temperature, we did not have data on directly measured drink temperatures,” Papier acknowledged. “Therefore, we cannot determine how self-reported drink temperature is likely to relate to absolute drink temperature.”

Despite the findings, Papier reassured coffee and tea lovers that there is no need to eliminate these beverages from their diets. “These findings don’t mean people need to stop drinking tea or coffee. Just let your drinks cool down a little before drinking them,” she advised.

Dr. Aaron Sasson, chief of surgical oncology and co-director of the gastrointestinal oncology team at Stony Brook Cancer Center in New York, echoed the study’s findings, noting that consuming hot liquids can irritate the esophagus and potentially contribute to the development of esophageal cancer. “The hotter the liquid, the higher the risk of a ‘thermal injury,'” Sasson explained. He likened the effect to sustaining a burn on the skin, which can increase the risk of skin cancer in the affected area.

Importantly, Dr. Sasson pointed out that the study specifically focused on the risk of squamous carcinomas, rather than adenocarcinomas. He noted that in the United States, about 85% of esophageal cancers are adenocarcinomas, making the incidence of squamous carcinomas relatively low. The lifetime risk of developing squamous cell carcinoma of the esophagus in the U.S. is less than 1%.

While acknowledging the study’s limitations, Dr. Sasson advised caution for those who consume large quantities of hot beverages. “If you are a heavy consumer of hot tea or coffee, maybe you’d want to cool it down a little bit,” he suggested. However, he emphasized that for most people, drinking hot beverages is not the predominant risk factor for developing esophageal squamous cell carcinoma.

Other well-established risk factors for esophageal cancer include smoking, heavy alcohol consumption, acid reflux, and obesity. Dr. Sasson concluded, “If you were to limit alcohol consumption and eliminate cigarette smoking, you will have done wonders for your esophagus.”

As research continues to explore the connections between lifestyle choices and cancer risk, this study serves as a reminder of the importance of moderation and awareness in our daily habits, particularly regarding the temperature of the beverages we consume.

According to Fox News, the findings underscore the need for further investigation into the health impacts of beverage temperatures.

The California Department of Public Health and the West Coast Health Alliance have released immunization recommendations for the 2026-2027 respiratory virus season, emphasizing the importance of vaccination for vulnerable populations.

SACRAMENTO – The California Department of Public Health (CDPH), in collaboration with the West Coast Health Alliance (WCHA), has issued new immunization recommendations for the upcoming 2026-2027 respiratory virus season. These guidelines are based on insights from reputable national medical organizations, including the American Academy of Pediatrics (AAP), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Family Physicians (AAFP).

Vaccination remains the most effective defense against respiratory viruses such as COVID-19, influenza, and respiratory syncytial virus (RSV). Seasonal immunization serves as a vital public health measure to mitigate severe illness, reduce hospitalization and mortality rates, curb community transmission, and alleviate pressure on the healthcare system.

The recommendations underscore the necessity of protecting those most vulnerable to respiratory viruses. This includes the youngest and oldest members of the community, individuals at higher risk for complications—such as pregnant individuals—those residing in congregate settings, and people who interact with high-risk populations. This year, there is a particular focus on safeguarding healthcare workers from serious illness as they continue to provide care for their communities.

“I am proud to work with our public health colleagues and immunization leaders in the other West Coast Health Alliance member states to update our recommendations and ensure our communities are well prepared and protected for the 2026-2027 respiratory virus season,” said Dr. Erica Pan, CDPH Director and State Public Health Officer.

Californians seeking COVID-19, influenza, and RSV vaccines can reach out to their health plans, healthcare providers, local public health clinics, or federally qualified health centers. Additionally, individuals can find a vaccination clinic through My Turn, California’s Vaccine Scheduling & Information Site.

For the latest information on respiratory virus activity in California, residents can visit the CDPH Respiratory Viruses Hub.

Vaccination recommendations for the 2026-2027 respiratory virus season are available in a PDF format, along with other current guidelines on the CDPH Vaccines for All webpage. All vaccines recommended by the California Department of Public Health are covered by health insurance plans regulated in California.

The West Coast Health Alliance is a collaborative effort among California, Hawaii, Oregon, and Washington, aimed at ensuring that public health recommendations are rooted in safety, efficacy, transparency, access, and trust.

For further details, refer to the CDPH’s official communications.

The FDA has approved Rasonque, a once-daily pill for advanced pancreatic cancer, which has shown to nearly double patient survival rates in clinical trials.

The U.S. Food and Drug Administration (FDA) announced the approval of a new cancer treatment pill, Rasonque, on Wednesday. Manufactured by Revolution Medicines in California, this innovative medication targets the RAS protein, which is responsible for driving 95% of pancreatic adenocarcinoma cases.

Rasonque is designed as an inhibitor for the most common type of pancreatic cancer and is taken once daily. In its press release, the FDA described Rasonque as a “new treatment option for patients with advanced pancreatic cancer,” highlighting that the approval was granted more than six months ahead of the agency’s review deadline.

Acting FDA Commissioner Kyle Diamantas emphasized the significance of this approval, stating, “Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.” He expressed pride in the FDA scientists whose diligent efforts made this milestone possible.

The authorization applies to adults suffering from metastatic pancreatic cancer who have either not responded to at least one prior treatment or are unable to receive certain combination drug therapies. Pancreatic adenocarcinoma is one of the deadliest forms of cancer in the United States, accounting for approximately 95% of the 67,000 annual pancreatic cancer cases reported by the National Cancer Institute.

Despite representing only 3.2% of total cancer diagnoses, pancreatic cancer leads to a disproportionately high number of cancer-related deaths due to its tendency to be diagnosed at advanced stages and its rapid progression.

The approval of Rasonque followed a randomized, open-label trial involving 500 patients with pre-treated metastatic disease. Results indicated that patients taking Rasonque achieved a median overall survival of 13.2 months, nearly double the 6.7-month survival rate observed in the standard chemotherapy control group. “This drug showed unprecedented results in an area of high unmet need,” remarked Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence.

The FDA expedited the drug’s market entry by granting it priority review, orphan drug status, and a breakthrough therapy designation. Additionally, the filing was assessed under the FDA commissioner’s National Priority Voucher pilot program, which aims to accelerate access to critical public health treatments.

Before the official approval, the agency issued a “safe to proceed” letter in May, which allowed for an expanded access protocol enabling patients to receive the drug prior to its final approval.

Safety profiles for Rasonque indicate that the most common adverse events associated with the drug include rash, diarrhea, mouth sores (stomatitis), nausea, fatigue, vomiting, abdominal pain, fluid retention (edema), reduced appetite, and bleeding (hemorrhage).

Dr. Anna Berkenblit, chief scientific and medical officer of the Pancreatic Cancer Action Network (PanCAN), described the approval as a landmark achievement, stating, “Today’s landmark approval is the most significant advance we have seen in the fight against pancreatic cancer, a devastating disease. I believe this drug will transform how pancreatic cancer is treated, giving people the opportunity for more time with loved ones, the possibility of a better quality of life, and optimism that continued research may lead to even greater advances.”

This groundbreaking development represents a significant step forward in the ongoing battle against one of the most challenging forms of cancer, offering hope to patients and their families.

According to Fox News, Rasonque’s approval marks a pivotal moment in oncology, particularly for those affected by pancreatic cancer.

ForSight Robotics’ JASPER platform has successfully completed 26 fully robotic-assisted cataract surgeries, all under the control of a surgeon, marking a significant step in surgical technology.

ForSight Robotics has announced that its JASPER Robotic Surgical Platform has completed 26 fully robotic-assisted cataract surgeries without transitioning to manual operation. This innovative approach aims to integrate robotic technology into a procedure that has become routine for many patients.

Cataract surgery is typically a straightforward process, with patients arriving at the clinic, undergoing the procedure, and often returning home the same day. The introduction of JASPER into this familiar routine represents a significant advancement in surgical technology.

According to ForSight, each of the 26 procedures was conducted entirely robotically, with the surgeon directing the operation through a process known as telemanipulation. This means that while the robot executed the precise movements required for the surgery, the surgeon remained in control, translating their commands into actions performed by the robotic instruments inside the patient’s eye.

The JASPER platform offers high-definition 3D visualization, allowing surgeons to see the surgical field in great detail. It also features capabilities to scale movements and filter out natural hand tremors, enhancing precision. Additionally, real-time eye tracking enables the robot to adjust as the eye moves during the procedure, ensuring accuracy throughout the operation.

ForSight’s robotic system is designed to perform the entire cataract surgery rather than just a portion of it, which distinguishes it from other robotic surgical systems. The surgeon maintains decision-making authority throughout the procedure, ensuring that the human element remains integral to the operation.

While robotic surgery is becoming more prevalent, JASPER’s approach emphasizes collaboration between the surgeon and the robotic system. This contrasts with other robotic systems that may operate more independently. For instance, previous reports highlighted an AI-powered robot that completed a key phase of gallbladder surgery autonomously, whereas JASPER requires continuous surgeon input.

Cataract surgery is one of the most commonly performed operations worldwide, with over 30 million procedures conducted annually. The potential impact of robotic systems like JASPER could be substantial, as they may enhance the efficiency and precision of surgeries that affect millions of patients each year.

Robotic surgery is also expanding beyond traditional operating rooms. Recent developments include a London surgeon remotely guiding a robot to perform prostate cancer surgery from 1,500 miles away. Such advancements illustrate the growing role of robotics in various surgical fields, including ophthalmology.

Despite the promising results from the initial 26 surgeries, it is important to note that this is still early clinical experience. The success of JASPER does not imply that it is ready for widespread use. ForSight is continuing its clinical work and preparing for further studies and regulatory submissions.

One notable statistic from the announcement is that 100% of the procedures were completed robotically without switching to manual surgery. While this figure is impressive, it is crucial to understand what it represents. It does not indicate a 100% success rate or prove that JASPER is safer than traditional cataract surgery. More extensive studies are needed to evaluate long-term outcomes and overall safety.

For patients currently considering cataract surgery, JASPER is not yet available as a commercial option. However, its development offers a glimpse into the future of surgical procedures. The potential for surgeons to control a robotic system that translates their decisions into precise movements could revolutionize how surgeries are performed, particularly in delicate areas like the eye.

As robotic technology continues to evolve, it may provide surgeons with greater stability and open new avenues for performing specialized procedures. However, the transition from successful trials with a small group of patients to a system suitable for widespread use will require further research and regulatory scrutiny.

The integration of robotic systems into existing surgical practices raises important questions about patient comfort and outcomes. As ForSight continues to develop the JASPER platform, the focus will be on ensuring that the technology enhances the surgical experience without complicating established procedures.

As the medical community explores the potential of robotic surgery, the balance between innovation and patient care remains paramount. The success of JASPER in these initial surgeries may pave the way for a future where robotic assistance becomes a standard part of cataract surgery, but larger studies and regulatory approvals will be essential to validate its efficacy and safety.

ForSight Robotics’ advancements in robotic cataract surgery offer an intriguing look at the future of eye care. As the technology progresses, it will be interesting to see how it integrates into the existing framework of surgical practices and whether it can deliver improved outcomes for patients.

As we await further developments, the question remains: would you feel comfortable undergoing cataract surgery with a robot performing the physical movements while a surgeon oversees the entire process? Your thoughts are welcome at Cyberguy.com.

According to ForSight Robotics, the journey of robotic surgery in cataract procedures is just beginning, and ongoing research will determine its future in clinical settings.

Popular NAD+-boosting supplements like NMN and nicotinamide riboside may hinder chemotherapy effectiveness in pancreatic cancer, according to a new study from Case Western Reserve University.

Over-the-counter anti-aging supplements, favored by millions of Americans for their potential to boost energy and mitigate chemotherapy side effects, may inadvertently compromise cancer treatments. A recent study conducted by researchers at Case Western Reserve University School of Medicine reveals that certain vitamin B3 derivatives—specifically nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and nicotinamide (NAM)—could enable cancer cells to survive chemotherapy.

These compounds play a crucial role in the production of NAD+, a molecule essential for cellular energy generation and damage repair. The study, published in the journal Cancer Letters, focused on how these supplements interact with treatments for pancreatic cancer, a particularly aggressive form of the disease with a five-year survival rate of only 13%, according to the American Cancer Society.

While increasing NAD+ levels through dietary supplements may provide health benefits to non-cancerous cells, the study found that pancreatic cancer cells could exploit the additional resources to repair chemotherapy-induced damage and evade cell death. In both laboratory settings and animal models, the supplements were shown to protect cancer cells from three commonly used chemotherapy drugs: oxaliplatin, 5-fluorouracil, and gemcitabine. Consequently, tumors were able to survive chemotherapy doses that would typically be lethal.

“Our findings highlight a potentially concerning role for NAD+-boosting supplements in the context of active cancer, especially when used in conjunction with chemotherapy,” said Jordan Winter, the study’s lead author and a professor at Case Western Reserve School of Medicine, as well as co-leader of the developmental therapeutics program at the Case Comprehensive Cancer Center. “Our discovery is a call to action for the medical community.”

The study indicates that while these B3 derivatives are generally considered safe for healthy individuals seeking overall wellness, the risks become more pronounced for patients undergoing active cancer therapy. “This research is a critical reminder that ‘natural’ doesn’t always mean safe, especially in the complex biology of cancer treatment,” Winter added.

In light of these findings, the research team recommends that oncology professionals routinely screen patients for supplement use. They also advocate for further studies to explore how NAD+ precursors interact with various cancer therapies.

Winter urged patients currently receiving treatment to consult their oncologists before taking any over-the-counter supplements. However, the study’s reliance on laboratory cell cultures and animal models means that the findings may not directly apply to human patients during treatment. Furthermore, the research was limited to pancreatic cancer, suggesting that the effects of these supplements on chemotherapy may differ for other cancer types or drug combinations.

Additionally, the study focused on short-term cellular responses in controlled laboratory conditions rather than human clinical trials, leaving unanswered questions about the long-term effects of these supplements on cancer patients.

Fox News Digital reached out to several NAD+ supplement manufacturers for comment.

According to Fox News, the implications of this research underscore the need for caution regarding the use of dietary supplements during cancer treatment.

The Phase 3 trial of an mRNA cancer vaccine developed by Merck and Moderna shows promise in preventing the recurrence and spread of melanoma in patients post-surgery.

In a landmark clinical trial, an experimental mRNA cancer vaccine developed by Merck and Moderna has demonstrated a significant reduction in the risk of melanoma returning or spreading after surgery. This Phase 3 trial marks a pivotal moment in cancer research, as it is the first positive outcome for an mRNA-based personalized cancer therapy.

The study, known as INTerpath-001, involved 1,137 patients worldwide who had undergone surgery to remove high-risk melanoma, classified as Stage IIB through Stage IV. Participants were randomly assigned to receive either Keytruda, a well-known immunotherapy, combined with the personalized vaccine, or Keytruda with a placebo.

Results indicated that patients receiving the combination therapy experienced significantly improved “recurrence-free survival,” meaning their cancer was less likely to return compared to those who received Keytruda alone. Additionally, the combination therapy also enhanced “distant metastasis-free survival,” which measures how long patients remain alive without cancer spreading to other parts of the body.

Stéphane Bancel, CEO of Moderna, emphasized the significance of these findings, stating, “These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational. We are now helping turn that vision into a reality.”

Unlike traditional vaccines that protect against external viruses, this custom-tailored mRNA vaccine, known as intismeran autogene, is a therapeutic vaccine administered after surgery. Its purpose is to train the body to identify and eliminate any remaining cancer cells.

After a tumor is surgically removed, doctors analyze both the cancerous tissue and healthy cells. Advanced algorithms then assess the tumor’s genetic sequence to select up to 34 tumor-specific neoantigens to encode in the personalized treatment.

Dr. Murad Alam, chief of dermatology at Northwestern Medicine in Chicago, highlighted the uniqueness of each melanoma, stating, “They’re slightly different in every patient, which is why traditional chemotherapies often stop working or don’t work in a particular patient.” He described the vaccine as an individualized immunotherapy that targets specific issues in each patient.

The individualized approach aims to direct the immune system toward tumor-specific targets, effectively distinguishing cancer cells from normal cells. Dr. Alam explained, “It doesn’t hit normal cells, and it hits the cancer cells very effectively because it’s not just a generic vaccine. It’s one that specifically knows the signs of your cancer and can find it.”

While the vaccine is designed to extend the lives of patients with advanced melanoma, it is not intended for individuals without the disease, even if they have a family history that may increase their risk. Dr. Alam clarified, “This is designed for people where the melanoma has grown to the point where it’s threatening not just the local area of the skin, but their whole lives.”

Artificial intelligence plays a crucial role in determining which antigens to include in the vaccine, enhancing its effectiveness. Dr. Alam noted, “These things are difficult, and, historically, [they] took a lot of time, and it just wouldn’t be feasible to do this for every individual patient without the power of AI. And I’m sure that will become better and better in the future.” AI allows for the efficient development of personalized vaccines tailored to individual patients.

Following the successful Phase 3 trial results, Merck and Moderna announced plans to engage with regulatory authorities worldwide, including the U.S. Food and Drug Administration, regarding potential regulatory filings. The companies are also exploring the application of this vaccine technology against other challenging cancers, such as lung, bladder, and kidney cancers.

Dr. Alam expressed optimism about the broader implications of this approach, stating, “I think the underlying concept of targeting a particular tumor with the specific markers on that tumor is generalizable, meaning you could do this with different kinds of skin cancer or different kinds of cancer in general. It’s very exciting.”

Despite the promising results, it is important to note that the findings are still in the early stages and did not specify how long patients remained cancer-free. Additionally, the Phase 3 trial results were based on investigator assessments rather than an independent central review. The study focused solely on patients with specific stages of melanoma who had undergone surgery and had no prior drug treatments, which may limit the applicability of the results to other cancer types or stages.

Merck reported that the side effects of the treatment were consistent with those observed in earlier studies, with no new safety concerns identified. Dr. Alam reiterated that the vaccine appears to offer both a “tremendous benefit [and] good side effect profile.” He added, “When you’re getting very strong cancer medications, even when they work, the toll on the patient is often terrible. It alters their life during the course of treatment where there’s tremendous suffering.” He noted that because the vaccine is so targeted, it minimizes damage to normal cells, resulting in milder side effects, such as fatigue, chills, and localized pain at the injection site.

As research continues, the potential of personalized mRNA vaccines in cancer treatment represents a significant advancement in the fight against melanoma and possibly other cancers in the future, according to Fox News.

Experts warn that taking oral Wegovy with morning coffee or tea may hinder the medication’s effectiveness in weight management.

Individuals using oral glucagon-like peptide-1 (GLP-1) medications, such as Wegovy tablets, are advised to avoid consuming morning coffee or tea when taking their medication. According to FDA prescribing information, Wegovy should be taken on an empty stomach with no more than 4 ounces of water, and no other liquids should be consumed at that time.

Patients are instructed to wait at least 30 minutes after taking the medication before eating, drinking other beverages, or taking any oral medications. As the first FDA-approved oral medication for chronic weight management, Wegovy has distinct guidelines compared to its injectable counterparts, particularly regarding how food and drink can affect absorption through the digestive system.

Dr. Michael Hall, a board-certified physician and longevity specialist, emphasized the importance of taking oral Wegovy correctly. “Oral Wegovy should be taken on an empty stomach, only with water,” he stated. “Coffee, tea, juice, or other drinks should not be taken with the pill because they can interfere with how the medicine is absorbed,” he explained to Fox News Digital.

For those using oral GLP-1 medications, Dr. Hall recommends a specific morning routine to ensure optimal absorption. “Food and beverages other than water, and other oral medicines, can affect absorption if taken too soon,” he noted. “The safest rule is 30 minutes of nothing by mouth except water after the tablet.”

Additionally, Dr. Hall pointed out that GLP-1 medications can slow stomach emptying, which may further impact the absorption of other oral medications.

Dr. Marc Siegel, a senior medical analyst for Fox News, concurred with Dr. Hall’s advice, stating that a GLP-1 pill should only be taken on an empty stomach with water. He mentioned that while drinking tea throughout the day generally does not interfere with oral GLP-1s or block their absorption, patients should still consult their physicians for personalized advice.

Dr. Siegel also highlighted that certain types of tea, such as green, black, and white teas, can aid digestion. Meanwhile, ginger and peppermint teas may help alleviate nausea, which can be beneficial for some patients.

Fox News Digital reached out to Wegovy’s manufacturer, Novo Nordisk, for further comment on the matter.

As the popularity of weight-loss medications like Wegovy continues to rise, understanding the proper administration and potential interactions with common beverages is crucial for users aiming to achieve effective results.

For more information on health and wellness, readers can refer to various health news sources and consult their healthcare providers for tailored guidance.

According to Fox News, following these guidelines can help ensure that users of oral Wegovy maximize the medication’s effectiveness in their weight management journey.

Recent research reveals that cancer treatment delays in the U.S. have increased significantly, prompting urgent calls for systemic improvements in healthcare delivery.

Wait times for cancer treatment in the United States have surged by nearly two weeks over the past decade, according to a recent study published in JAMA Surgery. The research, conducted by teams from the University of California, Los Angeles, and Massachusetts General Hospital, analyzed data from over two million patients diagnosed between January 2012 and December 2023.

The study focused on adults with early to locally advanced stages of six common cancers: breast, colon, lung, pancreatic, stomach, and esophageal. These patients received surgery as part of their initial treatment plan. Researchers measured the time from diagnosis to the commencement of treatment, which could either be surgical intervention or pre-surgical therapy aimed at shrinking tumors.

Across all six cancer types, the median wait times increased by more than 10 days during the study period. The most significant delays were observed in stomach cancer, where wait times rose from 35 days to 49 days, and lung cancer, which saw an increase from 41 days to 53 days. Breast cancer patients experienced delays that grew from 34 to 45 days, while colon cancer wait times increased from 20 to 31 days.

For pancreatic cancer, the wait extended from 23 to 32 days, and esophageal cancer delays increased from 38 to 48 days. The study also highlighted a troubling trend: a growing number of patients are now waiting 60 days or longer to begin treatment.

“This is part of our healthcare system that needs fixing immediately,” Dr. Marc Siegel, a senior medical analyst for Fox News, stated. He emphasized that these delays are evident even at high-volume academic medical centers, indicating a widespread issue within the healthcare system.

Dr. Siegel, who was not involved in the study, noted that waiting times for essential cancer surgeries in non-metastatic cases have been on the rise since 2012. The study’s findings revealed that the delays are not uniformly distributed among different demographic groups. Black patients, individuals on Medicaid, those living in lower-income areas, patients traveling longer distances for care, and those treated at academic medical centers or high-volume hospitals experienced longer wait times.

Geographically, the Western U.S. reported longer delays compared to other regions. Additionally, for non-breast cancers, the use of robotic surgery was associated with extended wait times.

The study authors cautioned that delays in surgical treatment have previously been linked to higher mortality rates and poorer long-term survival outcomes. In a supporting commentary published alongside the study, Dr. Lia D. Delaney and Dr. Sherry M. Wren from the Stanford School of Medicine noted that while cancer care has become increasingly sophisticated over the last two decades, the regionalization of care could inadvertently create barriers to timely treatment unless improvements in capacity and coordination are made simultaneously.

However, the study does have limitations. It relied on retrospective data from the National Cancer Database, which means it could not pinpoint the specific reasons behind individual treatment delays, such as scheduling conflicts, logistical challenges, or patient preferences. Furthermore, the database lacked information on when patients first developed symptoms or sought medical advice prior to their diagnosis.

As the healthcare system grapples with these challenges, the findings underscore the urgent need for reforms to ensure that patients receive timely and effective cancer treatment.

According to Fox News, the implications of these delays could be profound, affecting not only patient outcomes but also the overall efficacy of cancer care in the United States.

A recent study reveals that waist size may be a more accurate indicator of heart health than BMI, highlighting the risks associated with visceral fat around the abdomen.

A person’s waist size may reveal more about their heart health than the number on the scale, according to new research. A study found that waist measurements can identify potential cardiovascular risks that may be overlooked when doctors rely solely on body mass index (BMI).

Researchers from the Cross-Cohort Collaboration analyzed data from nearly 260,000 adults enrolled in 15 long-term health studies, following participants for approximately 20 years. The findings, published in the Journal of the American College of Cardiology, indicated that some individuals classified as normal weight based on BMI still exhibited higher levels of fat around their midsection.

Among participants in the normal and overweight BMI ranges, those with larger waist measurements or higher waist-to-hip ratios generally faced a 15% to 50% greater risk of various heart-related problems and mortality during the study period. These results suggest that examining how weight is distributed across the body may provide a more comprehensive understanding of health risks than BMI alone.

“BMI only tells us weight relative to height; it doesn’t indicate where fat is stored, and that matters,” said Erin Palinski-Wade, a New Jersey-based registered dietitian, certified diabetes educator, and author of The Sleepdemic Solution. Palinski-Wade, who was not involved in the study, emphasized that fat accumulated around the abdomen poses different health concerns compared to fat stored elsewhere in the body.

“Where you carry fat matters more than how much you carry, because visceral fat, the fat wrapped around abdominal organs, is metabolically active tissue that drives inflammation, insulin resistance, and artery damage in a way that subcutaneous fat does not,” she explained.

The research underscores why relying on BMI alone may not provide a complete picture of an individual’s heart health. “BMI doesn’t tell the whole story; where you carry fat may matter more than the number on the scale,” Palinski-Wade added.

Researchers examined several health outcomes over the course of the study, including heart attacks, strokes, heart failure, atrial fibrillation, and cardiovascular-related deaths. However, the study also noted several limitations, including the lack of information on participants’ physical activity, diets, or genetic predispositions to obesity, all of which can influence cardiovascular disease risk.

Additionally, the study measured waist circumference and waist-to-hip ratio only once, which limited researchers’ ability to assess how changes in abdominal fat over time may affect heart disease risk.

As the findings suggest, a more nuanced approach to assessing health risks may be necessary, one that considers both BMI and waist measurements. This could lead to better prevention strategies and health outcomes for individuals at risk of cardiovascular disease.

For more insights on health and wellness, visit Fox News Digital.

New research from the UK Biobank indicates that low wine consumption is associated with lower mortality rates compared to beer and spirits, while heavy drinking significantly increases death risk.

Heavy alcohol consumption has long been associated with increased mortality risk, but a recent study suggests that the type of beverage consumed at lower levels may also play a significant role. Research involving 340,924 participants from the UK Biobank has revealed that wine is linked to lower mortality rates, while beer and spirits are associated with higher death risks.

The data for this study was collected between 2006 and 2022, with participants undergoing an average follow-up period of more than 13 years. The findings were presented at the American College of Cardiology’s Annual Scientific Session held in New Orleans.

In the study, participants categorized their alcohol intake as never/occasional, low, moderate, or high. High consumption was defined as exceeding 40 grams of alcohol per day for men (approximately three standard drinks) and more than 20 grams per day for women (about 1.4 standard drinks). Those who reported high levels of alcohol consumption faced a 24% higher risk of all-cause mortality, a 36% increased risk of cancer-related death, and a 14% higher risk of cardiovascular death compared to individuals who never or occasionally drank.

However, the study found that the mortality risk associated with low or moderate alcohol consumption varied depending on the type of beverage consumed. Spirits, beer, and cider were linked to significantly higher mortality rates, while moderate wine consumption was associated with a notable reduction in mortality risk. Specifically, moderate wine drinkers had a 21% lower risk of cardiovascular death compared to those who abstained or drank infrequently.

Conversely, individuals who consumed low amounts of spirits, beer, or cider exhibited a 9% higher risk of cardiovascular death. Dr. Zhangling Chen, a professor at the Second Xiangya Hospital at Central South University in China and the study’s senior author, emphasized the importance of these findings. “These results come from the general population, and in certain high-risk groups, such as people with chronic diseases or cardiovascular conditions, the risks could be even higher,” he stated in a press release.

Dr. Chen noted that these findings could help refine public health guidance, highlighting that the health risks associated with alcohol consumption depend not only on the quantity consumed but also on the type of beverage.

One possible explanation for wine’s association with lower mortality rates could be its content of beneficial compounds such as polyphenols and antioxidants. These substances may positively impact blood vessel health, inflammation, and overall cardiovascular well-being.

Jessica Steinman, a Los Angeles-based addiction specialist and chief clinical officer for No Matter What Recovery, acknowledged the study’s insights but cautioned against applying the findings too broadly, particularly for individuals with a history of substance misuse. “When we hear these stories or get this research, it becomes a ‘black and white’ larger generalization for the population, and we want to be careful with that,” she told Fox News Digital.

Steinman emphasized that not everyone should consume alcohol daily, regardless of the type. “If there’s someone who’s struggling with substances, then they really shouldn’t be having it at all,” she advised. She pointed out that different alcoholic beverages contain varying levels of alcohol, and individual metabolism of alcohol can differ significantly.

Steinman recommended consulting with a medical professional for personalized guidance regarding alcohol consumption. “Overall, more is not better, but also the higher potency of alcohol and higher percentages of alcohol is going to affect people negatively as well,” she added.

The researchers acknowledged several limitations in their study. As it was observational in nature, the research could not definitively establish that wine consumption leads to lower mortality rates or that other alcoholic beverages directly cause higher mortality. Additionally, participants reported their baseline alcohol intake at the study’s outset, meaning any changes in drinking habits during the follow-up period were not captured.

Furthermore, the researchers noted that wine drinkers might have different dietary or lifestyle habits that could influence their health outcomes. The UK Biobank participants are generally healthier than the overall population, which may limit the generalizability of the findings.

The authors of the study called for high-quality randomized trials to further investigate the relationship between drinking habits and mortality risk.

These findings underscore the complexity of alcohol consumption and its health implications, suggesting that moderation and beverage choice are critical factors in determining the associated risks.

According to Fox News, the study serves as a reminder that while moderate wine consumption may have certain health benefits, individual circumstances and health histories should guide personal decisions regarding alcohol intake.